Clinical Trials Logo

Kidney; Complications, Allograft clinical trials

View clinical trials related to Kidney; Complications, Allograft.

Filter by:
  • None
  • Page 1

NCT ID: NCT02294032 Completed - Clinical trials for Transplantation Infection

The Role of B Cells in Kidney Allograft Dysfunction

Start date: August 28, 2014
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to understand the role of specific B cells in activating or repressing an anti-allograft immune response after kidney transplantation. In this study, blood will be collected from kidney transplant patients during different timepoints, prior to and after their transplant. Knowledge gained from study findings will be used to develop therapeutic strategies to prevent antibody-mediated rejection, which is a major cause of long-term graft loss in kidney transplant patients.

NCT ID: NCT02036554 Recruiting - Clinical trials for Kidney; Complications, Allograft

Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients

PROTECT
Start date: March 2013
Phase: Phase 4
Study type: Interventional

To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus after transplantation in the renal allograft recipients

NCT ID: NCT01327573 Completed - Clinical trials for Kidney; Complications, Allograft

Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation

Start date: March 2011
Phase: Phase 1
Study type: Interventional

This study is designed to assess the effectiveness of eculizumab in recipients of kidney transplantation with donor-specific antibodies (DSA) and worsening kidney function and to assess if eculizumab improves endothelial cell injury in the kidney. The investigators hypothesize that complement inhibition with eculizumab will reduce allograft injury, resulting from less complement-mediated injury of endothelial cells and less endothelial cell activation.